PTC Therapeutics, Inc. Forecast, price target & analysts
PTC Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
PTC Therapeutics, Inc. Classifications & Recommendation:
PTC Therapeutics, Inc. Price Target
| Target Price | $62.64 |
| Price | $50.57 |
| Potential |
23.87%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target PTC Therapeutics, Inc. 2026 .
The average PTC Therapeutics, Inc. target price is $62.64.
This is
23.87%
register free of charge
$113.00
123.45%
register free of charge
$41.00
18.92%
register free of charge
|
|
| A rating was issued by 15 analysts: 9 Analysts recommend PTC Therapeutics, Inc. to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the PTC Therapeutics, Inc. stock has an average upside potential 2026 of
23.87%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 937.82 | 803.68 |
| 34.20% | 14.30% | |
| EBITDA Margin | -12.03% | -5.54% |
| 72.98% | 53.94% | |
| Net Margin | -68.68% | -42.64% |
| 19.94% | 37.91% |
13 Analysts have issued a sales forecast PTC Therapeutics, Inc. 2024 . The average PTC Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an PTC Therapeutics, Inc. EBITDA forecast 2024. The average PTC Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 PTC Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average PTC Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -8.37 | -4.45 |
| 7.45% | 46.83% | |
| P/E | negative | |
| EV/Sales | 4.13 |
14 Analysts have issued a PTC Therapeutics, Inc. forecast for earnings per share. The average PTC Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the PTC Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
PTC Therapeutics, Inc....
Current PTC Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital | Locked ➜ Locked | Locked | Feb 18 2025 |
| Citigroup | Locked ➜ Locked | Locked | Feb 12 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Feb 03 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Jan 15 2025 |
| Morgan Stanley | Locked ➜ Locked | Locked | Dec 13 2024 |
| Citigroup | Locked ➜ Locked | Locked | Dec 04 2024 |
| Goldman Sachs | Locked ➜ Locked | Locked | Dec 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 18 2025 |
|
Locked
Citigroup: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Feb 03 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Jan 15 2025 |
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Dec 13 2024 |
|
Locked
Citigroup: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Dec 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
